Key result
A 65-year-old woman developed reversible cancer therapeutics-related cardiac dysfunction and intracardiac thrombi following treatment with bevacizumab and epirubicin for breast cancer.
Case Report (n=1)
This case highlights that severe cancer therapeutics-related cardiac dysfunction with intracardiac thrombi induced by bevacizumab and epirubicin can be fully reversible with appropriate guideline-directed heart failure and anticoagulation therapy.
Answers are grounded in this paper and cite their sources.
Supports possible reversibility of bevacizumab-related cardiomyopathy with thrombi; hypothesis-generating and should not change practice.
Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart failure or arterial thromboembolism has been reported as a rare cardiovascular complication of bevacizumab. We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.
No takes yet. Share an insight, caveat, or question.
Tsujinaga et al. (2020) conducted a case report in Cancer therapeutics-related cardiac dysfunction and intracardiac thrombi (n=1). Bevacizumab and epirubicin was evaluated. A 65-year-old woman developed reversible cancer therapeutics-related cardiac dysfunction and intracardiac thrombi following treatment with bevacizumab and epirubicin for breast cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: